Clearmind Medicine regains compliance with Nasdaq minimum bid price rule

Clearmind Medicine (CMND) received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). On December 30, Nasdaq provided confirmation to the Company that for the last 10 consecutive business days, from December 15 through December 29, the closing bid price of the Company’s common shares was $1.00 per share or greater, that the Company has hence regained compliance with Listing Rule 5550(a)(2) and that the matter is now closed.